Format

Send to

Choose Destination
Blood. 2016 Dec 8;128(23):e59-e66. Epub 2016 Oct 14.

PDGFB, a new candidate plasma biomarker for venous thromboembolism: results from the VEREMA affinity proteomics study.

Author information

1
Coagulation Unit, Hematology Centre, Karolinska University Hospital, Stockholm, Sweden.
2
Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
3
Department of Proteomics, School of Biotechnology, Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden.
4
Institute of Cardiometabolism and Nutrition Institute for Cardiometabolism and Nutrition, Paris, France.
5
Unitat d'Hemostàsia i Trombosi, IIB-Sant Pau, Barcelona, Spain.
6
Department of Numerical Analysis and Computer Science, Stockholm University, Stockholm, Sweden.
7
Unitat de Genòmica de Malalties Complexes, IIB-Sant Pau, Barcelona, Spain.
8
Sorbonne Paris Cité, Université Paris Descartes, Paris, France.
9
INSERM UMR-S1140, Faculté de Pharmacie de Paris, Paris, France.
10
l'Assistance Publique-Hôpitaux de Paris, Service d'Hématologie Biologique, Hôpital Européen Georges Pompidou, Paris, France.
11
Clinical Chemistry, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
12
Institute for Clinical Chemistry and Laboratory Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
13
Aix-Marseille University, UMR_S 1062, Nutrition Obesity and Risk of Thrombosis, Marseille, France.
14
Laboratory of Hematology, La Timone Hospital, Marseille, France; and.
15
Sorbonne Universités, Pierre and Marie Curie University University of Paris 06, INSERM, UMR_S 1166, Team Genomics and Pathophysiology of Cardiovascular Diseases, Paris, France.

Abstract

There is a clear clinical need for high-specificity plasma biomarkers for predicting risk of venous thromboembolism (VTE), but thus far, such markers have remained elusive. Utilizing affinity reagents from the Human Protein Atlas project and multiplexed immuoassays, we extensively analyzed plasma samples from 2 individual studies to identify candidate protein markers associated with VTE risk. We screened plasma samples from 88 VTE cases and 85 matched controls, collected as part of the Swedish "Venous Thromboembolism Biomarker Study," using suspension bead arrays composed of 755 antibodies targeting 408 candidate proteins. We identified significant associations between VTE occurrence and plasma levels of human immunodeficiency virus type I enhancer binding protein 1 (HIVEP1), von Willebrand factor (VWF), glutathione peroxidase 3 (GPX3), and platelet-derived growth factor β (PDGFB). For replication, we profiled plasma samples of 580 cases and 589 controls from the French FARIVE study. These results confirmed the association of VWF and PDGFB with VTE after correction for multiple testing, whereas only weak trends were observed for HIVEP1 and GPX3. Although plasma levels of VWF and PDGFB correlated modestly (ρ ∼ 0.30) with each other, they were independently associated with VTE risk in a joint model in FARIVE (VWF P < .001; PDGFB P = .002). PDGFΒ was verified as the target of the capture antibody by immunocapture mass spectrometry and sandwich enzyme-linked immunosorbent assay. In conclusion, we demonstrate that high-throughput affinity plasma proteomic profiling is a valuable research strategy to identify potential candidate biomarkers for thrombosis-related disorders, and our study suggests a novel association of PDGFB plasma levels with VTE.

PMID:
27742707
DOI:
10.1182/blood-2016-05-711846
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center